A randomized phase-II trial comparing sequential and concurrent paclitaxel with oral or parenteral fluorinated pyrimidines for advanced or metastatic gastric cancer

Gastric Cancer

Volumn 15, Issue 4, 2012, Pages 363-369

  Nishikawa, Kazuhiro ^a   Morita, Satoshi ^b   Matsui, Takanori ^c   Kobayashi, Michiya ^d   Takeuchi, Yoji ^e   Takahashi, Ikuo ^f   Sato, Seiji ^g   Miyashita, Yumi ^h   Tsuburaya, Akira ⁱ   Sakamoto, Junichi ^j   Kakeji, Yoshihiro ^k   Baba, Hideo ^l  

^a OSAKA GENERAL MEDICAL CENTER   (Japan)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

^c AICHI CANCER CENTER HOSPITAL   (Japan)

^d KOCHI MEDICAL SCHOOL   (Japan)

^e OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^f MATSUYAMA RED CROSS HOSPITAL   (Japan)

^g Saga Prefectural Hospital Koseikan   (Japan)

^h Epidemiological and Clinical Research Information Network   (Japan)

ⁱ KANAGAWA CANCER CENTER   (Japan)

^j NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^k KYUSHU UNIVERSITY   (Japan)

^l KUMAMOTO UNIVERSITY   (Japan)

more..

Author keywords

Advanced gastric cancer; Concurrent combination chemotherapy; Paclitaxel; Randomized phase II trial; S 1; Sequential chemotherapy

Indexed keywords

FLUOROURACIL; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DIARRHEA; DRUG TREATMENT FAILURE; FATIGUE; FEMALE; FOLLOW UP; HUMAN; LASSITUDE; LEUKOPENIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MONOTHERAPY; NAUSEA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STOMACH CANCER; STOMATITIS; SURVIVAL RATE; THROMBOCYTE; TREATMENT RESPONSE; VOMITING; WEIGHT REDUCTION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG COMBINATIONS; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, PARENTERAL; MALE; MIDDLE AGED; OXONIC ACID; PACLITAXEL; PATIENT COMPLIANCE; STOMACH NEOPLASMS; TEGAFUR; TREATMENT OUTCOME;

EID: 84870321915     PISSN: 14363291     EISSN: 14363305     Source Type: Journal    
DOI: 10.1007/s10120-011-0124-3     Document Type: Article

References (22)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55: 74-108.
2. Glimelius B, Ekstrom K, Hoffman K, Graf W, Sjödén PO, Haglund U, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol. 1997;8: 163-8.
3. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer. 1993;72: 37-41.
4. Pyrhönen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer. 1995;71: 587-91.
5. Ohtsu A, Shimada Y, Shirao K, Boku N, Hyodo I, Saito H, et al. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol. 2003;21: 54-9.
6. Boku N, Yamamoto S, Fukuda H, Shirao K, Doi T, Sawaki A, et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol. 2009;10: 1063-9.
7. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9: 215-21.
8. Sakamoto J, Matsui T, Kodera Y. Paclitaxel chemotherapy for the treatment of gastric cancer. Gastric Cancer. 2009;12: 69-78.
9. Ajani JA, Fairweather J, Dumas P, Patt YZ, Pazdur R, Mansfield PF. Phase II study of Taxol in patients with advanced gastric carcinoma. Cancer J Sci Am. 1998;4: 269-74.
10. Murad AM, Petroianu A, Guimaraes RC, Aragao BC, Cabral LO, Scalabrini-Neto AO. Phase II trial of the combination of paclitaxel and 5-fluorouracil in the treatment of advanced gastric cancer: a novel, safe, and effective regimen. Am J Clin Oncol. 1999;22: 580-6.
11. Ninomiya M, Kondo K, Matsuo K, Hirabayashi N, Kojima H, Kobayashi M, et al. Multicenter phase II trial of combination chemotherapy with weekly paclitaxel and 5-fluorouracil, for the treatment of advanced or recurrent gastric carcinoma. J Chemother. 2007;19: 444-50.
12. Ueda Y, Yamagishi H, Ichikawa D, Okamoto K, Otsuji E, Morii J, et al. Multicenter phase II study of weekly paclitaxel plus S-1 combination chemotherapy in patients with advanced gastric cancer. Gastric Cancer. 2010;13: 149-54.
13. Morita S, Baba H, Tsuburaya A, Takiuchi H, Matsui T, Maehara Y, et al. A randomized phase II selection trial in patients with advanced/recurrent gastric cancer: Trial for Advanced Stomach Cancer (TASC). Jpn J Clin Oncol. 2007;37: 469-72.
14. Kaplan EL, Meier P. Nonparametric estimation form incomplete observations. J Am Stat Assoc. 1958;53: 457-81.
15. Cox DR, Oakes D. Analysis of survival data. London: Chapman and Hall; 1984.
16. Simon R, Wittes RE, Ellenberg SS. Randomized phase II clinical trials. Cancer Treat Rep. 1985;69: 1375-81.
17. Narahara H, Iishi H, Imamura H, Tsuburaya A, Chin K, Imamoto H, et al. Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002). Gastric Cancer. 2011;14: 72-80.
18. Kim YH, Koizumi W, Lee KH, Kishimoto T, Chung HC, Hara T, et al. Randomized phase III study of S-1 alone versus S-1 ? docetaxel in the treatment for advanced gastric cancer (The START trial). J Clin Oncol. 2011;29 (4s; ASCO Gastrointestinal Cancers Symposium Abstract 7).
19. Sledge GW, Neuberg D, Bernardo P, Ingle JN, Martino S, Rowinsky EK, et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol. 2003;21: 588-92.
20. Miller KD, McCaskill-Stevens W, Sisk J, Loesch DM, Monaco F, Seshadri R, et al. Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: a randomized pilot trial of the Hoosier Oncology Group. J Clin Oncol. 1999;17: 3033-7.
21. Ioka T, Ikeda M, Ohkawa S, Yanagimoto H, Fukutomi A, Sugimori K,et al. Randomized phase III study of gemcitabine plus S-1 (GS) versus S-1 versus gemcitabine (GEM) in unresectable advanced pancreatic cancer (PC) in Japan and Taiwan: GEST study. J Clin Oncol. 2011;29 (15s; ASCO Annual Meeting Abstract 4007).
22. Ajani JA, Rodriguez W, Bodoky G, Moiseyenko V, Lichinitser M, Gorbunova V, et al. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol. 2010;28: 1547-53.